DOCSLIB.ORG

X Congress of the Italian Society of Experimental Hematology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
X Congress of the Italian Society of Experimental Hematology Owned & published by the Ferrata Storti Foundation, Pavia, Italy Editor-in-Chief Mario Cazzola (Pavia) Associate Editors Clara Camaschella (Milan), Elias Campo (Barcelona), Jan Cools (Leuven), Elihu Estey (Seattle), Randy Gascoyne (Van- couver), Michael Laffan (London), Pieter H. Reitsma (Leiden), Jesus F. San Miguel (Salamanca), Birgit Schlegelberger (Hannover), Freda K. Stevenson (Southampton), Matthias Theobald (Utrecht), Ivo P. Touw (Rotterdam) Assistant Editors Luca Malcovati (Deputy Editor), Gaetano Bergamaschi (CME), Anne Freckleton (English Editor), Rosangela Invernizzi (CME), Cristiana Pascutto (Statistical Consultant), Rachel Stenner (English Editor), Vittorio Rosti (CME) Editorial Board Walter Ageno (Varese), Maurizio Aricò (Firenze), Paolo Arosio (Brescia), Yesim Aydinok (Izmir), Giuseppe Basso (Pado- va), Sigbjørn Berentsen (Haugesund), Erik Berntorp (Malmö), Jackie Boultwood (Oxford), David Bowen (Leeds), Moni- ka Bruggemann (Kiel), Oystein Bruserud (Bergen), Michele Cavo (Bologna), Francisco Cervantes (Barcelona), Oliver Cor- nely (Köln), Javier Corral (Murcia), Francesco Dazzi (London), Marcos De Lima (Houston), Valerio De Stefano (Roma), Ruud Delwel (Rotterdam), Meletios A. Dimopoulos (Athens), Inderjeet Dokal (London), Hervet Dombret (Paris), Johannes Drach (Vienna), Peter Dreger (Hamburg), Martin Dreyling (München), Sabine Eichinger (Vienna), Emmanuel Favaloro (Westmead), Augusto Federici (Milano), Jean Feuillard (Limoges), Letizia Foroni (London), Jonathan W. Fried- berg (Rochester), Dave Gailani (Nashville), Renzo Galanello (Cagliari), Carlo Gambacorti-Passerini (Monza), Guiller- mo Garcia Manero (Houston), Christian Geisler (Copenhagen), James N. George (Oklahoma City), Ulrich Germing (Düs- seldorf), Paolo Ghia (Milano), Piero Giordano (Leiden), Corrado Girmenia (Roma), Mark T. Gladwin (Bethesda), Thomas M. Habermann (Rochester), Claudia Haferlach (München), Christine Harrison (Southampton), Claire Harrison (Lon- don), Andreas Hochhaus (Mannheim), Ulrich Jaeger (Vienna), Leonid Karawajew (Berlin), Gregory Kato (Bethesda), John Koreth (Boston), Robert Kralovics (Vienna), Nicolaus Kröger (Hamburg), Thomas J. Kunicki (La Jolla), Ralf Küppers (Essen), Marco Ladetto (Torino), David Jacobsohn (Chicago), Ola Landgren (Bethesda), Jean Jacques Lataillade (Clamart), Veronique Leblond (Paris), Roberto Lemoli (Bologna), Per Ljungman (Stockholm), Francesco Lo Coco (Roma), Henk M. Lokhorst (Utrecht), Rita Maccario (Pavia), Guido Marcucci (Columbus), Judith Marsh (London), Giampaolo Merlini (Pavia), Anna Rita Migliaccio (Roma), Constantine S. Mitsiades (Boston), Mohamad Mohty (Nantes), Rosario Notaro (Firenze), Johannes Oldenburg (Bonn), Jan Palmblad (Stockholm), Animesh Pardanani (Rochester), Jakob Passweg (Gene- va), Louis Pelus (Indianapolis), Melanie J. Percy (Belfast), Rob Pieters (Rotterdam), Stefano Pileri (Bologna), Miguel Piris (Madrid), Paolo Prandoni (Padova), Jerald P. Radich (Seattle), Andreas Reiter (Mannheim), Mats Remberger (Stock- holm), Josep-Maria Ribera (Barcelona), Francesco Rodeghiero (Vicenza), Radek C. Skoda (Basel), Roberto Stasi (Albano Laziale), David P. Steensma (Rochester), Martin H. Steinberg (Boston), David Stroncek (Bethesda), Ronald Taylor (Char- lottesville), Evangelos Terpos (Athens), Xavier Thomas (Lyon), Armando Tripodi (Milano), Han-Mou Tsai (New York), Alvaro Urbano-Ispizua (Sevilla), Alessandro M. Vannucchi (Firenze), Edo Vellenga (Groningen), Umberto Vitolo (Tori- no), Guenter Weiss (Innsbruck), Mervin Yoder (Indianapolis), Alberto Zanella (Milano) Editorial Office Michele Moscato (Production Manager), Lorella Ripari (Peer Review Manager), Matteo Giovanni Della Porta (Peer Review), Paola Cariati (Production), Igor Ebuli Poletti (Production), Marta Fossati (Peer Review) Affiliated Scientific Societies SIE (Italian Society of Hematology, www.siematologia.it) AEHH (Spanish Association of Hematology and Hemotherapy, www.aehh.org) SETH (Spanish Society of Thrombosis and Hemostasis, www.seth.es) SIES (Italian Society of Experimental Hematology, www.sies.ws) SISET (Italian Society for Studies on Hemostasis and Thrombosis, www.siset.org) AIEOP (Italian Association of Pediatric Hematology/Oncology, www.aieop.org) EAHP (European Association for Haematopathology, www.socforheme.org/eahp) SIdEM (Italian Society of Hemapheresis and Cellular Manipulation, www.emaferesi.it) Oggi, il mondo di domani Oggi, il mondo di domani è l’impegno ad agire per un presente responsabile ed un futuro sostenibile. Per Bristol-Myers Squibb significa innanzitutto sviluppare farmaci che realmente possano fare la differenza nella vita delle persone per prolungare e migliorare la vita umana. Ma significa anche avere la piena consapevolezza degli obblighi verso la comunità locale e globale, trasformandoli in impegno concreto. Il nostro impegno guarda al futuro e alle realtà più lontane ma inizia nel presente e dai luoghi a noi più vicini. Oggi, per il domani. .bms.it www European Hematology Association (EHA) EHA is a scientific society aiming to support research, education and clinical practice in hematology. Its main objective is to be useful to scientific researchers, clinicians, medical students, as well as all those working in other fields but who are interested in hematology. The European Hematology Association was founded in June 1992. Today, EHA – with over 3000 active members from 95 countries – is a consolidated organization that pursues a large and growing number of projects and programs. EHA aims to promote – Exchange and dissemination of knowledge and scientific information in the field of hematology. – Education and training in hematology. – Medical practice in the area of hematology and the position of hematology as medical discipline. – Scientific research in hematology. – Exchange of information for all European doctors, scientists and other professionals interested in hematology. – A unified European training program in hematology in collaboration with European National Societies of Hematology. In order to achieve these goals, EHA – Maintains regular contacts and organizes meetings with all European National Societies of Hematology. – Holds an annual scientific and educational congress in a major European city; European Cooperative Groups and Networks are encouraged to take advantage of this major event to gather. – Disseminates medical research, both basic and clinic, through the new journal Haematologica/The Hematology Journal. – Has established a link with European National Societies of Hematology and other organizations such as the European Group for Bone Marrow Transplantation, European Association for Hematopathology, European Society of Medical Oncology, and American Society of Hematology. – Provides postgraduate education through the annual congresses, seminars, courses, workshops and meetings organized in collaboration with the European School of Haematology. – Has a Fellowship/Grants Program to promote research in hematology. – Accredits scientific meetings and provides CME accounts in collaboration with the European National Societies for hematology. If you recognize the need for a strong European Hematology Association and would like to take advantage of the various activities of the Association, you may wish to become a member of the EHA and contribute to its objectives. Benefits of EHA Membership – Subscription to Haematologica/ The Hematology Journal, including on-line access – Reduced registration fee for EHA Annual Congresses – Eligible to EHA Research Fellowships & Grants – EHA Newsletter – Access to EHA membership database – Access to webcast sessions of the EHA Annual Congress – Entitled to apply for a scholarship to attend ESH-EHA scientific workshops www.ehaweb.org Con la sua ampia gamma di prodotti e servizi, in grado di dare aiuto a pazienti in oltre 90 paesi nel mondo, Genzyme è leader nello sviluppo e nella applicazione delle più avanzate tecnologie nel campo delle scienze della vita. La Società è focalizzata sulle malattie genetiche rare, l’insufficienza renale, l’oncologia, i trapianti e le malattie immunitarie, l’ortopedia e i test diagnostici. L’impegno di Genzyme verso l’innovazione, prosegue attraverso programmi di sviluppo importanti tanto nelle attuali aree terapeutiche quanto in altre aree, tra le quali quelle di alcune patologie cardiovascolari, dove ancora mancano soluzioni terapeutiche adeguate. Genetica Diagnostica Ortopedia Biomateriali Insuffi cienza renale Malattie genetiche Oncologia Trapianti Malattie immunitarie www.genzyme.it New submission and tracking system On September 1st, 2008, Haematologica adopted Bench>Press as its new web-based manuscript submission and tracking system. Below you find some new instructions regarding submission of papers. Original Articles across all areas of experimental and clinical hematology are the prototype of papers the journal is looking for. Brief Reports are just shorter papers, which must provide conclusive findings: preliminary observations or incomplete findings cannot be considered for publication. Case Reports are no longer considered for publication: please do not submit them as Brief Reports, unless they include peculiar studies such as those concerning molecular basis of disease. Review Articles are typically solicited by the Editors, but the journal may also consider reviews submitted on authors’ own initiative: pre-submission inquiries are welcome. Decision Making and Problem Solving papers typically include meta-analyses, guidelines and position papers by scientific societies. Letters to the Editor should
Load more

Recommended publications
  • The T-ALL Related Gene BCL11B Regulates the Initial Stages of Human T-Cell Differentiation
    Leukemia (2017) 31, 2503–2514 © 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 0887-6924/17 www.nature.com/leu ORIGINAL ARTICLE The T-ALL related gene BCL11B regulates the initial stages of human T-cell differentiation VL Ha1, A Luong1,FLi2, D Casero3, J Malvar1,YMKim1,4, R Bhatia5, GM Crooks3,6,7,8 and C Parekh1,4 The initial stages of T-cell differentiation are characterized by a progressive commitment to the T-cell lineage, a process that involves the loss of alternative (myelo-erythroid, NK, B) lineage potentials. Aberrant differentiation during these stages can result in T-cell acute lymphoblastic leukemia (T-ALL). However, the mechanisms regulating the initial stages of human T-cell differentiation are obscure. Through loss of function studies, we showed BCL11B, a transcription factor recurrently mutated T-ALL, is essential for T-lineage commitment, particularly the repression of NK and myeloid potentials, and the induction of T-lineage genes, during the initial stages of human T-cell differentiation. In gain of function studies, BCL11B inhibited growth of and induced a T-lineage transcriptional program in T-ALL cells. We found previously unknown differentiation stage-specific DNA binding of BCL11B at multiple T-lineage genes; target genes showed BCL11B-dependent expression, suggesting a transcriptional activator role for BCL11B at these genes. Transcriptional analyses revealed differences in the regulatory actions of BCL11B between human and murine thymopoiesis. Our studies show BCL11B is a key regulator of the initial stages of human T-cell differentiation and delineate the BCL11B transcriptional program, enabling the dissection of the underpinnings of normal T-cell differentiation and providing a resource for understanding dysregulations in T-ALL.
    [Show full text]
  • MLL1 and DOT1L Cooperate with Meningioma-1 to Induce Acute Myeloid Leukemia
    MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia Simone S. Riedel, … , Tobias Neff, Kathrin M. Bernt J Clin Invest. 2016;126(4):1438-1450. https://doi.org/10.1172/JCI80825. Research Article Oncology Meningioma-1 (MN1) overexpression is frequently observed in patients with acute myeloid leukemia (AML) and is predictive of poor prognosis. In murine models, forced expression of MN1 in hematopoietic progenitors induces an aggressive myeloid leukemia that is strictly dependent on a defined gene expression program in the cell of origin, which includes the homeobox genes Hoxa9 and Meis1 as key components. Here, we have shown that this program is controlled by two histone methyltransferases, MLL1 and DOT1L, as deletion of either Mll1 or Dot1l in MN1-expressing cells abrogated the cell of origin–derived gene expression program, including the expression of Hoxa cluster genes. In murine models, genetic inactivation of either Mll1 or Dot1l impaired MN1-mediated leukemogenesis. We determined that HOXA9 and MEIS1 are coexpressed with MN1 in a subset of clinical MN1hi leukemia, and human MN1hi/HOXA9hi leukemias were sensitive to pharmacologic inhibition of DOT1L. Together, these data point to DOT1L as a potential therapeutic target in MN1hi AML. In addition, our findings suggest that epigenetic modulation of the interplay between an oncogenic lesion and its cooperating developmental program has therapeutic potential in AML. Find the latest version: https://jci.me/80825/pdf RESEARCH ARTICLE The Journal of Clinical Investigation MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia Simone S. Riedel,1 Jessica N. Haladyna,1 Matthew Bezzant,1 Brett Stevens,2 Daniel A.
    [Show full text]
  • USP29 Is a Novel Non-Canonical Hypoxia Inducible Factor-Α Activator
    bioRxiv preprint doi: https://doi.org/10.1101/2020.02.20.957688; this version posted February 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 USP29 is a novel non-canonical Hypoxia Inducible Factor-α 2 activator 3 4 Amelie S Schober1,2, Inés Martín-Barros1, Teresa Martín-Mateos1, Encarnación Pérez- 5 Andrés1, Onintza Carlevaris1, Sara Pozo1, Ana R Cortazar1, Ana M Aransay1,3, Arkaitz 6 Carracedo1,4,5,6, Ugo Mayor5,6, Violaine Sée2, Edurne Berra1,4* 7 8 (1) Centro de Investigación Cooperativa en Biociencias CIC bioGUNE, Basque Research and Technology 9 Alliance (BRTA), Parque Tecnológico de Bizkaia-Ed.801A, 48160 Derio, Spain. 10 (2) Institute of Integrative Biology, Department of Biochemistry, Centre for Cell Imaging, University of 11 Liverpool, L69 7ZB Liverpool, United Kingdom. 12 (3) Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 28029 13 Madrid, Spain. 14 (4) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain. 15 (5) Department of Biochemistry and Molecular Biology, University of the Basque Country (UPV/EHU), Leioa, 16 Bizkaia, Spain. 17 (6) Ikerbasque, Basque Foundation for Science, 48011 Bilbao, Bizkaia, Spain. 18 (*) correspondence: [email protected] (+34 946 572 506) 19 20 21 22 23 24 25 26 27 28 Running title: USP29 deubiquitinates HIF-α 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.02.20.957688; this version posted February 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • Latent Herpes Simplex Virus Infection of Sensory Neurons Alters Neuronal Gene Expression Martha F
    JOURNAL OF VIROLOGY, Sept. 2003, p. 9533–9541 Vol. 77, No. 17 0022-538X/03/$08.00ϩ0 DOI: 10.1128/JVI.77.17.9533–9541.2003 Copyright © 2003, American Society for Microbiology. All Rights Reserved. Latent Herpes Simplex Virus Infection of Sensory Neurons Alters Neuronal Gene Expression Martha F. Kramer,1,2 W. James Cook,3† Frederick P. Roth,1 Jia Zhu,2 Holly Holman,2 David M. Knipe,2* and Donald M. Coen1* Departments of Biological Chemistry and Molecular Pharmacology1 and Microbiology and Molecular Genetics,2 Harvard Medical School, Boston, and Millennium Pharmaceuticals, Cambridge,3 Massachusetts Received 17 March 2003/Accepted 3 June 2003 The persistence of herpes simplex virus (HSV) and the diseases that it causes in the human population can be attributed to the maintenance of a latent infection within neurons in sensory ganglia. Little is known about the effects of latent infection on the host neuron. We have addressed the question of whether latent HSV infection affects neuronal gene expression by using microarray transcript profiling of host gene expression in ganglia from latently infected versus mock-infected mouse trigeminal ganglia. 33P-labeled cDNA probes from pooled ganglia harvested at 30 days postinfection or post-mock infection were hybridized to nylon arrays 4 ؍ printed with 2,556 mouse genes. Signal intensities were acquired by phosphorimager. Mean intensities (n replicates in each of three independent experiments) of signals from mock-infected versus latently infected ganglia were compared by using a variant of Student’s t test. We identified significant changes in the expression of mouse neuronal genes, including several with roles in gene expression, such as the Clk2 gene, and neurotransmission, such as genes encoding potassium voltage-gated channels and a muscarinic acetylcholine receptor.
    [Show full text]
  • The Deubiquitinating Enzyme USP20 Regulates the Tnfα-Induced NF-Κb Signaling Pathway Through Stabilization of P62
    International Journal of Molecular Sciences Article The Deubiquitinating Enzyme USP20 Regulates the TNFα-Induced NF-κB Signaling Pathway through Stabilization of p62 Jihoon Ha y, Minbeom Kim y, Dongyeob Seo, Jin Seok Park, Jaewon Lee, Jinjoo Lee and Seok Hee Park * Department of Biological Sciences, Sungkyunkwan University, Suwon 16419, Korea; [email protected] (J.H.); [email protected] (M.K.); [email protected] (D.S.); [email protected] (J.S.P.); [email protected] (J.L.); [email protected] (J.L.) * Correspondence: [email protected]; Tel.: +82-31-290-5912 These authors contributed equally to this work. y Received: 9 April 2020; Accepted: 27 April 2020; Published: 28 April 2020 Abstract: p62/sequestosome-1 is a scaffolding protein involved in diverse cellular processes such as autophagy, oxidative stress, cell survival and death. It has been identified to interact with atypical protein kinase Cs (aPKCs), linking these kinases to NF-κB activation by tumor necrosis factor α (TNFα). The diverse functions of p62 are regulated through post-translational modifications of several domains within p62. Among the enzymes that mediate these post-translational modifications, little is known about the deubiquitinating enzymes (DUBs) that remove ubiquitin chains from p62, compared to the E3 ligases involved in p62 ubiquitination. In this study, we first demonstrate a role of ubiquitin-specific protease USP20 in regulating p62 stability in TNFα-mediated NF-κB activation. USP20 specifically binds to p62 and acts as a positive regulator for NF-κB activation by TNFα through deubiquitinating lysine 48 (K48)-linked polyubiquitination, eventually contributing to cell survival. Furthermore, depletion of USP20 disrupts formation of the atypical PKCζ-RIPK1-p62 complex required for TNFα-mediated NF-κB activation and significantly increases the apoptosis induced by TNFα plus cycloheximide or TNFα plus TAK1 inhibitor.
    [Show full text]
  • 2016 Joint Meeting Program
    April 15 – 17, 2016 Fairmont Chicago Millennium Park • Chicago, Illinois The AAP/ASCI/APSA conference is jointly provided by Boston University School of Medicine and AAP/ASCI/APSA. Meeting Program and Abstracts www.jointmeeting.org www.jointmeeting.org Special Events at the 2016 AAP/ASCI/APSA Joint Meeting Friday, April 15 Saturday, April 16 ASCI President’s Reception ASCI Food and Science Evening 6:15 – 7:15 p.m. 6:30 – 9:00 p.m. Gold Room The Mid-America Club, Aon Center ASCI Dinner & New Member AAP Member Banquet Induction Ceremony (Ticketed guests only) (Ticketed guests only) 7:00 – 10:00 p.m. 7:30 – 9:45 p.m. Imperial Ballroom, Level B2 Rouge, Lobby Level How to Solve a Scientific Puzzle: Speaker: Clara D. Bloomfield, MD Clues from Stockholm and Broadway The Ohio State University Comprehensive Cancer Center Speaker: Joe Goldstein, MD APSA Welcome Reception & University of Texas Southwestern Medical Center at Dallas Presidential Address APSA Dinner (Ticketed guests only) 9:00 p.m. – Midnight Signature Room, 360 Chicago, 7:30 – 9:00 p.m. John Hancock Center (off-site) Rouge, Lobby Level Speaker: Daniel DelloStritto, APSA President Finding One’s Scientific Niche: Musings from a Clinical Neuroscientist Speaker: Helen Mayberg, MD, Emory University Dessert Reception (open to all attendees) 10:00 p.m. – Midnight Imperial Foyer, Level B2 Sunday, April 17 APSA Future of Medicine and www.jointmeeting.org Residency Luncheon Noon – 2:00 p.m. Rouge, Lobby Level 2 www.jointmeeting.org Program Contents General Program Information 4 Continuing Medical Education Information 5 Faculty and Speaker Disclosures 7 Scientific Program Schedule 9 Speaker Biographies 16 Call for Nominations: 2017 Harrington Prize for Innovation in Medicine 26 AAP/ASCI/APSA Joint Meeting Faculty 27 Award Recipients 29 Call for Nominations: 2017 Harrington Scholar-Innovator Award 31 Call for Nominations: George M.
    [Show full text]
  • 1 the Functional Interplay Between the HIF Pathway and the Ubiquitin System
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2017 The functional interplay between the HIF pathway and the ubiquitin system – more than a one-way road Günter, Julia ; Ruiz-Serrano, Amalia ; Pickel, Christina ; Wenger, Roland H ; Scholz, Carsten C Abstract: The hypoxia inducible factor (HIF) pathway and the ubiquitin system represent major cellular processes that are involved in the regulation of a plethora of cellular signaling pathways and tissue func- tions. The ubiquitin system controls the ubiquitination of proteins, which is the covalent linkage of one or several ubiquitin molecules to specific targets. This ubiquitination is catalyzed by approximately 1000 different E3 ubiquitin ligases and can lead to different effects, depending on the type of internal ubiquitin chain linkage. The best-studied function is the targeting of proteins for proteasomal degradation. The activity of E3 ligases is antagonized by proteins called deubiquitinases (or deubiquitinating enzymes), which negatively regulate ubiquitin chains. This is performed in most cases by the catalytic removal of these chains from the targeted protein. The HIF pathway is regulated in an oxygen-dependent manner by oxygen-sensing hydroxylases. Covalent modification of HIF฀ subunits leads to the recruitment ofan E3 ligase complex via the von Hippel-Lindau (VHL) protein and the subsequent polyubiquitination and proteasomal degradation of HIF฀ subunits, demonstrating the regulation of the HIF pathway by the ubiq- uitin system. This unidirectional effect of an E3 ligase on the HIF pathway is the beststudied example for the interplay between these two important cellular processes. However, additional regulatory mechanisms of the HIF pathway through the ubiquitin system are emerging and, more recently, also the reciprocal regulation of the ubiquitin system through components of the HIF pathway.
    [Show full text]
  • Aneuploidy: Using Genetic Instability to Preserve a Haploid Genome?
    Health Science Campus FINAL APPROVAL OF DISSERTATION Doctor of Philosophy in Biomedical Science (Cancer Biology) Aneuploidy: Using genetic instability to preserve a haploid genome? Submitted by: Ramona Ramdath In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Science Examination Committee Signature/Date Major Advisor: David Allison, M.D., Ph.D. Academic James Trempe, Ph.D. Advisory Committee: David Giovanucci, Ph.D. Randall Ruch, Ph.D. Ronald Mellgren, Ph.D. Senior Associate Dean College of Graduate Studies Michael S. Bisesi, Ph.D. Date of Defense: April 10, 2009 Aneuploidy: Using genetic instability to preserve a haploid genome? Ramona Ramdath University of Toledo, Health Science Campus 2009 Dedication I dedicate this dissertation to my grandfather who died of lung cancer two years ago, but who always instilled in us the value and importance of education. And to my mom and sister, both of whom have been pillars of support and stimulating conversations. To my sister, Rehanna, especially- I hope this inspires you to achieve all that you want to in life, academically and otherwise. ii Acknowledgements As we go through these academic journeys, there are so many along the way that make an impact not only on our work, but on our lives as well, and I would like to say a heartfelt thank you to all of those people: My Committee members- Dr. James Trempe, Dr. David Giovanucchi, Dr. Ronald Mellgren and Dr. Randall Ruch for their guidance, suggestions, support and confidence in me. My major advisor- Dr. David Allison, for his constructive criticism and positive reinforcement.
    [Show full text]
  • Hypoxia and Aging Eui-Ju Yeo1
    Yeo Experimental & Molecular Medicine (2019) 51:67 https://doi.org/10.1038/s12276-019-0233-3 Experimental & Molecular Medicine REVIEW ARTICLE Open Access Hypoxia and aging Eui-Ju Yeo1 Abstract Eukaryotic cells require sufficient oxygen (O2) for biological activity and survival. When the oxygen demand exceeds its supply, the oxygen levels in local tissues or the whole body decrease (termed hypoxia), leading to a metabolic crisis, threatening physiological functions and viability. Therefore, eukaryotes have developed an efficient and rapid oxygen sensing system: hypoxia-inducible factors (HIFs). The hypoxic responses are controlled by HIFs, which induce the expression of several adaptive genes to increase the oxygen supply and support anaerobic ATP generation in eukaryotic cells. Hypoxia also contributes to a functional decline during the aging process. In this review, we focus on the molecular mechanisms regulating HIF-1α and aging-associated signaling proteins, such as sirtuins, AMP-activated protein kinase, mechanistic target of rapamycin complex 1, UNC-51-like kinase 1, and nuclear factor κB, and their roles in aging and aging-related diseases. In addition, the effects of prenatal hypoxia and obstructive sleep apnea (OSA)- induced intermittent hypoxia have been reviewed due to their involvement in the progression and severity of many diseases, including cancer and other aging-related diseases. The pathophysiological consequences and clinical manifestations of prenatal hypoxia and OSA-induced chronic intermittent hypoxia are discussed in detail. Introduction chemoreceptors stimulates the neurotransmitter release 3 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; Oxygen (O2) plays critical roles in aerobic respiration pathway and modulates the activity of a neutral endo- and metabolism as the final electron acceptor of the peptidase, neprilysin (NEP), which modifies the cellular mitochondrial electron transport chain, which is respon- response to hypoxia by hydrolyzing substance P4.
    [Show full text]
  • Characterization of VHL Missense Mutations in Sporadic Clear Cell
    Razafinjatovo et al. BMC Cancer (2016) 16:638 DOI 10.1186/s12885-016-2688-0 RESEARCH ARTICLE Open Access Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance Caroline Razafinjatovo1*, Svenja Bihr2, Axel Mischo2, Ursula Vogl3, Manuela Schmidinger4, Holger Moch1 and Peter Schraml1 Abstract Background: The VHL protein (pVHL) is a multiadaptor protein that interacts with more than 30 different binding partners involved in many oncogenic processes. About 70 % of clear cell renal cell carcinoma (ccRCC) have VHL mutations with varying impact on pVHL function. Loss of pVHL function leads to the accumulation of Hypoxia Inducible Factor (HIF), which is targeted by current targeted treatments. In contrast to nonsense and frameshift mutations that highly likely nullify pVHL multipurpose functions, missense mutations may rather specifically influence the binding capability of pVHL to its partners. The affected pathways may offer predictive clues to therapy and response to treatment. In this study we focused on the VHL missense mutation pattern in ccRCC, and studied their potential effects on pVHL protein stability and binding partners and discussed treatment options. Methods: We sequenced VHL in 360 sporadic ccRCC FFPE samples and compared observed and expected frequency of missense mutations in 32 different binding domains. The prediction of the impact of those mutations on protein stability and function was assessed in silico. The response to HIF-related, anti-angiogenic treatment of 30 patients with known VHL mutation status was also investigated. Results: We identified 254 VHL mutations (68.3 % of the cases) including 89 missense mutations (35 %).
    [Show full text]
  • BAALC, the Human Member of a Novel Mammalian Neuroectoderm Gene Lineage, Is Implicated in Hematopoiesis and Acute Leukemia
    BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia Stephan M. Tanner*, Jamie L. Austin*, Gustavo Leone*†, Laura J. Rush*‡, Christoph Plass*, Kristiina Heinonen§, Krzysztof Mro´ zek†, Heinz Sill¶, Sakari Knuutilaʈ, Jonathan E. Kolitz**, Kellie J. Archer†, Michael A. Caligiuri*†, Clara D. Bloomfield†, and Albert de la Chapelle*†,†† *Human Cancer Genetics Program, Ohio State University, 646 Medical Research Facility, 420 West 12th Avenue, Columbus, OH 43210; ‡Department of Veterinary Biosciences, Ohio State University, Columbus, OH 43210; §Department of Clinical Genetics, Kuopio University Hospital, 70211 Kuopio, Finland; †Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210; ¶Division of Hematology, Department of Medicine, Karl-Franzens University, 8010 Graz, Austria; ʈDepartment of Medical Genetics, Haartman Institute and Helsinki University Central Hospital, 00014 Helsinki, Finland; and **Don Monti Division of Medical Oncology͞Division of Hematology, North Shore University Hospital, New York University School of Medicine, Manhasset, NY 11030 Contributed by Albert de la Chapelle, October 3, 2001 The molecular basis of human leukemia is heterogeneous. Cyto- cDNA-based representational difference analysis (cDNA- genetic findings are increasingly associated with molecular abnor- RDA), a method that compares relative expression levels malities, some of which are being understood at the functional and allows previously unknown genes to be detected and level.
    [Show full text]
  • BAALC-Associated Gene Expression Profiles Define IGFBP7 As a Novel
    Leukemia (2010) 24, 1429–1436 & 2010 Macmillan Publishers Limited All rights reserved 0887-6924/10 www.nature.com/leu ORIGINAL ARTICLE BAALC-associated gene expression profiles define IGFBP7 as a novel molecular marker in acute leukemia S Heesch1,2, C Schlee1, M Neumann1, A Stroux3,AKu¨hnl1, S Schwartz1, T Haferlach4, N Goekbuget5, D Hoelzer5, E Thiel1, W-K Hofmann6 and CD Baldus1 1Charite´ Universita¨tsmedizin Berlin, Campus Benjamin Franklin, Medizinische Klinik III, Berlin, Germany; 2Freie Universita¨t Berlin, Institut fu¨r Biologie, Chemie und Pharmazie, Berlin, Germany; 3Charite´ Universita¨tsmedizin Berlin, Campus Benjamin Franklin, Institut fu¨r Biometrie und klinische Epidemiologie, Berlin, Germany; 4MLL Mu¨nchner Leuka¨mie Labor, Mu¨nchen, Germany; 5Johann Wolfgang Goethe-Universita¨t, Medizinische Klinik II, Frankfurt/Main, Germany and 6Universita¨t Heidelberg, Medizinische Fakulta¨t Mannheim, Medizinische Klinik III, Mannheim, Germany Over expression of BAALC (brain and acute leukemia, cyto- In a search for genes involved in leukemia, the human gene plasmic) predicts an inferior outcome in acute myeloid BAALC (brain and acute leukemia, cytoplasmic) located on leukemia (AML) and acute lymphoblastic leukemia patients. human chromosome 8q22.3 was identified.5 It was shown that To identify BAALC-associated genes that give insights into its functional role in chemotherapy resistance, gene expression over expression of BAALC was associated with an inferior signatures differentiating high from low BAALC expressers outcome and chemotherapy
    [Show full text]